Entero Healthcare Solutions Limited has informed the Exchange about Investor Presentation
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Entero Healthcare Solutions reported Q1 FY26 revenue of ₹1,404 crore, up 28% year-on-year, significantly outpacing the Indian pharmaceutical market (IPM) growth of 9%. Profit after tax rose 47% to ₹30.2 crore. Gross margin expanded to 9.9% (from 9.1%) and EBITDA margin improved to 3.6% (from 2.8%), driven by higher value-added services, margin-accretive categories, and procurement efficiencies. The company serves 71,000+ retail pharmacies and 2,500+ hospitals through 102 warehouses across 469 districts. Return ratios improved sharply with RoCE at 11.5% (vs 8.5%) and RoE at 9.0% (vs 5.7%). Entero has completed 50 acquisitions since inception, with 4 more pending closing, and has fully utilized ₹237 crore of IPO proceeds for inorganic growth.
Strong quarter with revenue growth far ahead of the industry, expanding margins, and improving return ratios signals healthy operational momentum. The company's aggressive acquisition-driven consolidation strategy in a fragmented market could continue to drive growth, potentially supporting a positive stock reaction.